Personal Use Import (FDA): how it works and where it is recognized

Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.

What Personal Use Import (FDA) is

Origin and authorising body. United States, FDA Regulatory Procedures Manual Chapter 9-2 (Personal Importation Policy). The authorising body for each individual case is the United States Food and Drug Administration (FDA) and US Customs and Border Protection (CBP), acting under that jurisdiction's pharmacy or medicines legislation.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Legal basis. The FDA Personal Importation Policy is set out in the FDA Regulatory Procedures Manual Chapter 9-2. The policy is an exercise of enforcement discretion: the FDA does not generally take action against the personal importation of small quantities of a medicine when the medicine is for a serious condition for which effective treatment is not available in the US, the medicine is not for commercial distribution, the quantity is not more than a three-month supply, the patient affirms in writing that the medicine is for personal use, and the patient provides the name and address of the licensed physician overseeing treatment.

Personal Use Import (FDA) is the United States framework for individual-patient import of medicines not approved in the US. The framework is enforcement-discretion-based rather than statutory: the FDA reserves the right to take action against any personal import but generally exercises discretion not to do so when the policy criteria are met. The framework is most commonly used by US patients with rare diseases obtaining medicines approved in the EU, UK, or Japan but not in the US.

Because the framework is enforcement-discretion-based rather than a positive authorisation, US Customs and Border Protection (CBP) screens shipments at the port of entry and may consult with the FDA. Shipments may be detained or refused entry even when the policy criteria appear to be met. Patients typically work with their treating physician and a coordinator to ensure documentation is in order before shipment. The FDA has tightened enforcement in defined categories (notably certain controlled substances and biologics) and patients should not assume that historical patterns continue to apply.

This page consolidates Reserve Meds's operational view of the Personal Use Import (FDA) framework across the ten destination countries where we currently coordinate cross-border supply. Earlier in our content build we maintained separate per-country sub-pages for each Personal Use Import (FDA)-in-country combination; those sub-pages remain available for archival reference but are no longer separately indexed, and the operational intelligence they carried has been folded into the country-compatibility table below.

Reserved for you.

Who can use Personal Use Import (FDA)

Personal Use Import (FDA) is used by US patients (or their treating physicians on their behalf) to import medicines not approved in the US for the patient's personal use. The framework is most often invoked for rare-disease therapies approved abroad but not yet in the US.

In practical terms, a Reserve Meds case opens when the treating physician has identified the clinical need, has reached a decision to prescribe a specific medicine, and has determined that the locally available route is unsuitable or unavailable. We then layer the regulatory and supply-chain coordination on top of that clinical decision; we do not originate the prescribing question and we do not advise on the clinical choice. The decision sits with the physician throughout.

Drug categories typically covered under Personal Use Import (FDA)

Rare-disease therapies approved abroad but not in the US, specialty oncology agents approved in the EU or UK but not in the US, paediatric formulations, and medicines withdrawn from the US market still available elsewhere.

The medicine itself must be source-country approved or in active regulatory development under a recognised reference authority (typically the US FDA, the European Medicines Agency, the UK MHRA, the Japan PMDA, or Health Canada). Most destination regulators will not authorise a Personal Use Import (FDA) import for a medicine that lacks a recognised reference authorisation anywhere in the world, because the regulator's risk assessment leans on the source-country review as a substitute for its own.

Country compatibility

The table below summarises how the Personal Use Import (FDA) framework is recognised across the ten destination countries where Reserve Meds currently coordinates cross-border supply. The "Accepts Personal Use Import (FDA) dossiers" column reflects whether the destination regulator typically reviews and grants permits on the strength of a Personal Use Import (FDA) clinical justification packet, or whether the patient must use a different parallel framework on the receiving side. Timelines reflect routine cases with a complete documentation set; first-import scenarios, paediatric weight-banded presentations, advanced therapy medicinal products, and large multi-cycle quantities can extend the regulator review by several weeks.

Notes. "Indirect" means the destination regulator does not directly accept Personal Use Import (FDA) authorisation as the legal basis for import but does recognise a Personal Use Import (FDA) authorisation as supporting precedent within its own named-patient or compassionate-use review. "Not applicable" means the framework is not a patient-access pathway in the cross-border sense and is shown here for completeness. Regulator names: NHRA (Bahrain), EDA (Egypt), CDSCO (India), JFDA (Jordan), KDFC (Kuwait), MoPH (Lebanon), MoH-DGPADC (Oman), MoPH-DPA (Qatar), SFDA (Saudi Arabia), and EDE (United Arab Emirates, federal from 29 December 2025).

Documentation required

A Personal Use Import (FDA) application is typically assembled in coordination with the treating physician, the dispensing facility, and the cross-border supply partner. The documentation set below covers the routine case; specific destination countries may require additional items (most frequently a hospital ethics committee notification for paediatric or complex cases, and an insurer pre-authorisation letter where the patient intends to seek reimbursement).

• Written patient affirmation that the medicine is for personal use.
• US-licensed physician's name and address.
• Clinical justification including diagnosis and absence of US-approved alternatives.
• Quantity calculation (typically three months).
• Customs documentation per CBP requirements.
• For controlled substances: additional DEA documentation may be required.

Typical timeline

US customs clearance: typically 5 to 14 business days. CBP may detain shipments for FDA consultation, which can add weeks. End-to-end: 2 to 6 weeks for routine cases.

Costs and reimbursement

Drug cost is the source-country acquisition cost plus international logistics, customs, and any coordinator fees. US insurer reimbursement for personal imports is uncommon.

Where Reserve Meds fits in

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine access. For Personal Use Import (FDA) cases, we coordinate the US-side sourcing through a DSCSA-compliant specialty channel, prepare the documentation packet your physician submits, coordinate validated cold-chain logistics with continuous temperature logging into the destination country, and assign a single named coordinator through the case. We do not replace your treating physician, we do not replace the destination-country regulator, and we do not replace your dispensing pharmacy. We coordinate the supply side so the physician can focus on patient care.

For each of the ten destination countries above, we publish a country-specific page documenting the operational realities (which dispensing facilities handle named-patient cases, how the cold chain is verified at the local airport, how the dispensing pharmacy releases the medicine, and what the typical insurer interaction looks like). Those country pages, combined with this pathway page and the specific drug pages, give the prescribing physician and the patient a coherent picture of what to expect before any commitment is made.

Our concierge fee is itemised separately on every firm quote alongside the drug acquisition cost, international logistics, customs, and dispensing pharmacy handling. The patient sees the full breakdown before deciding to proceed; we do not bundle costs and we do not charge an intake deposit. If the case cannot proceed for regulatory or supply reasons, we say so before any payment is taken.

Next step

If your treating physician has identified a clinical need that fits the Personal Use Import (FDA) framework and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your caseWhatsApp

Reserved for you.

---

Related

• All access pathways
• UAE access landscape
• Saudi Arabia: SFDA named-patient pathway
• When conventional access fails
• How Reserve Meds works